Cargando…

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells

We have extended our analyses of HDAC inhibitor biology in sarcoma. The multi-kinase inhibitor axitinib interacted with multiple HDAC inhibitors to kill sarcoma cells. Axitinib and HDAC inhibitors interacted in a greater than additive fashion to inactivate AKT, mTORC1 and mTORC2, and to increase Rap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roberts, Jane L., Booth, Laurence, Poklepovic, Andrew, Dent, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483767/ https://www.ncbi.nlm.nih.gov/pubmed/34604061 http://dx.doi.org/10.3389/fonc.2021.723966

Ejemplares similares

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

Fingolimod Augments Monomethylfumarate Killing of GBM Cells
por: Dent, Paul, et al.
Publicado: (2020)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells
por: Dent, Paul, et al.
Publicado: (2020)

HDAC inhibitors enhance the immunotherapy response of melanoma cells
por: Booth, Laurence, et al.
Publicado: (2017)

GZ17-6.02 and axitinib interact to kill renal carcinoma cells
por: Booth, Laurence, et al.
Publicado: (2022)

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2016)

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling
por: Booth, Laurence, et al.
Publicado: (2020)

Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling
por: Booth, Laurence, et al.
Publicado: (2021)

Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells
por: Tavallai, Mehrad, et al.
Publicado: (2015)

GZ17-6.02 kills prostate cancer cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2022)

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic
por: Tavallai, Mehrad, et al.
Publicado: (2016)

GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells
por: Booth, Laurence, et al.
Publicado: (2021)

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species
por: Roberts, Jane L., et al.
Publicado: (2017)

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2019)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]
por: Booth, Laurence, et al.
Publicado: (2017)

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS
por: Tavallai, Mehrad, et al.
Publicado: (2016)

GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins
por: Booth, Laurence, et al.
Publicado: (2021)

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide
por: Booth, Laurence, et al.
Publicado: (2016)

Kinase inhibitors: look beyond the label on the bottle
por: Dent, Paul, et al.
Publicado: (2019)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies
por: Dent, Paul, et al.
Publicado: (2019)

Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43
por: Dent, Paul, et al.
Publicado: (2021)

AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication
por: Rayner, Jonathan O., et al.
Publicado: (2020)

AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy
por: Dent, Paul, et al.
Publicado: (2022)

GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells
por: Booth, Laurence, et al.
Publicado: (2022)

OSU‐03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood–Brain Barrier: Implications for Anti‐Cancer Therapies
por: Booth, Laurence, et al.
Publicado: (2015)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
por: Booth, Laurence, et al.
Publicado: (2016)

Presurgical avelumab plus axitinib in an immunosenescent octogenarian with renal cell carcinoma invading the vena cava
por: Uematsu, Toshitaka, et al.
Publicado: (2022)

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
por: Booth, Laurence, et al.
Publicado: (2017)

Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells
por: Krcek, Reinhardt, et al.
Publicado: (2017)

Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report
por: Uekawa, Ayano, et al.
Publicado: (2022)

Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
por: Boutros, Andrea, et al.
Publicado: (2022)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report
por: Shimizu, Nobuaki, et al.
Publicado: (2021)

Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma
por: Lin, Dengqiang, et al.
Publicado: (2023)

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy
por: Cruickshanks, Nichola, et al.
Publicado: (2013)

A case of von Hippel–Lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy
por: Akioka, Takahiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_li1lpbj5l281nthqj4ajc2r8qf